Director/PDMR Shareholding

By

Regulatory News | 14 Apr, 2020

Updated : 07:38

RNS Number : 5304J
Circassia Pharmaceuticals Plc
14 April 2020
 

Director/PDMR Shareholding

Oxford, UK - 14 April 2020: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, today announces that on 9 April 2020, Ian Johnson, Executive Chairman of Circassia purchased 200,000 Ordinary Shares at a price of 22.85 pence per share, Michael Roller, Chief Financial Officer purchased 200,000 Ordinary Shares at a price of 22.683 pence per share and Jonathan Emms, Chief Operating Officer of Circassia, purchased 300,000 Ordinary Shares at a price of 23.2 pence per share.

Following these purchases, Ian Johnson holds 200,000 Ordinary Shares (0.05% of the issued share capital of the Company), Michael Roller holds 200,000 Ordinary Shares (0.05% of the issued share capital of the Company) and Jonathan Emms holds 600,000 Ordinary Shares (0.16% of the issued share capital of the Company).

Contacts

Circassia Pharmaceuticals plc

Ian Johnson Executive Chairman

Michael Roller Chief Financial Officer

c/o FTI Consulting

 

 

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel / Oliver Jackson

 

Tel:  +44 (0)20 7418 8900

finnCap (Joint Broker)

Geoff Nash / Alice Lane

 

Tel: +44 (0) 20 7220 0500

Numis Securities (Joint Broker)

James Black / Duncan Monteith

 

Tel: +44 (0) 20 7260 1000

FTI Consulting

Simon Conway / Ciara Martin

Tel: +44 (0) 20 3727 1000


 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.           

Details of the person discharging managerial responsibilities / person closely associated

a.            

Name

1. Ian Johnson

2. Michael Roller

3. Jonathan Emms

2.            

Reason for the notification

a.            

Position/status

1. Executive Chairman

2. Chief Financial Officer

3. Chief Operating Officer

b.            

Initial notification

/Amendment

 

Initial notification

3.            

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.           

Name

Circassia Pharmaceuticals plc

b.           

LEI

2138006YAT138TOGA556

4.            

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.            

Description of the

Financial instrument, type of instrument

Identification code

Ordinary Shares of 0.08p each

 

 

GB00BJVD3B28

b.            

Nature of the transaction

Purchase of Ordinary Shares

 

c.            

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

1.    22.85p

2.    22.683p

3.    23.2p

1.    200,000

2.    200,000

3.    300,000

      

d.            

Aggregated information

·    Aggregated volume

·    Price

 

 

 

n/a

 

e.            

Date of the transaction

2020-04-09

f.            

Place of the transaction

London Stock Exchange, AIM

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGLGDSCDBDGGS

Last news